Noticias de investigación
Among women who had breast cancer surgery and axillary lymph node dissection, Black and Hispanic women were more likely to develop lymphedema than white women, as were women who received chemotherapy before surgery, rather than after surgery.
In the years following a DCIS (ductal carcinoma in situ) diagnosis, about one in five invasive breast cancers that developed were not related to the original DCIS lesion.
During external whole-breast radiation therapy for breast cancer, women with large breasts who lay facedown had fewer skin side effects than women who lay faceup.
Fezolinetant, an experimental medicine that doesn’t contain hormones, has successfully treated hot flashes.
Many Black people diagnosed with metastatic breast cancer never find out about clinical trials from their doctors even though most of them are open to participating in one.
Black and Hispanic women who had low levels of vitamin D in their blood were more likely to develop breast cancer than women with sufficient levels.
People who received cancer treatment within three months of being diagnosed with COVID-19 had a higher risk of being hospitalized, being admitted to intensive care, or dying from COVID-19 than people who haven’t been diagnosed with cancer.
In women with extremely dense breasts and a high risk of breast cancer, screening with 3D mammograms — rather than 2D digital mammograms — was linked to a lower risk of advanced-stage disease.
Women ages 55 and older diagnosed with early-stage, estrogen receptor-positive, progesterone receptor-positive, HER2-negative breast cancer that had low levels of Ki67 protein and a very low risk of recurrence were able to safely skip radiation after lumpectomy.
Compared with doctors’ choice of chemotherapy, Enhertu (chemical name: fam-trastuzumab-deruxtecan-nxki) improved both progression-free survival and overall survival in people diagnosed with previously treated metastatic HER2-low breast cancer.
In the United States, people receiving breast cancer treatment had higher mortality risk when they had financial problems versus when they didn’t.
Rates of screening mammograms among women who’ve received breast cancer treatment have declined since 2009, especially among women ages 40 to 49.
Women were satisfied with their breasts 10 years after either lumpectomy and radiation or mastectomy and reconstruction for early-stage breast cancer. Still, women who had lumpectomy and radiation had better psychosocial and sexual well-being.
Previous chemotherapy treatment, more belly fat, and being less physically fit led to a lower immune response to a typhoid vaccine in women who’d been treated for breast cancer.
Infertility seems to double the risk of breast cancer in men.
Doctors should recommend regular aerobic and resistance exercise for people receiving cancer treatment.
Women with a history of invasive breast cancer had a higher risk of developing high blood pressure and diabetes than women without a history of breast cancer.
People diagnosed with cancer who’ve received a COVID-19 vaccine have a higher risk of a breakthrough COVID infection than vaccinated people without cancer.
Trodelvy (chemical name: sacituzumab govitecan-hziy) slightly improved progression-free survival in people diagnosed with metastatic hormone receptor-positive, HER2-negative breast cancer previously treated with hormonal therapy, a CDK4/6 inhibitor, and multiple lines of chemotherapy.
Kanjinti (trastuzumab-anns), a biosimilar for Herceptin used to treat people diagnosed with HER2-positive breast cancer, is now available in the United States.
People diagnosed with cancer developed COVID-19 antibodies after receiving the Moderna vaccine, but at lower levels than people who hadn’t been diagnosed with cancer.
Not exercising and lots of sitting can be harmful for cancer survivors.
Researchers have developed a tool that may help doctors figure out who has the highest risk of fatigue after breast cancer treatment.
Women are 34% more likely to have severe side effects during and after cancer treatment than men.